- Home
- CYCN vs TPST Comparison
CYCN vs TPST Comparison
Compare CYCN & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | TPST |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 15.6M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CYCN | TPST |
|---|---|---|
| Price | $3.89 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 23.5K | ★ 245.8K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,074,000.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $1.03 | $0.84 |
| 52 Week High | $8.48 | $12.22 |
Technical Indicators
Market Signals| Indicator | CYCN | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 52.69 |
| Support Level | $2.93 | $1.02 |
| Resistance Level | $3.97 | $1.09 |
| Average True Range (ATR) | 0.36 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 35.66 | 52.95 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.